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Abstract
In a previous study, we uncovered the anticonvulsant properties of turmeric oil and its sesquiterpenoids (ar-
turmerone, α-, β-turmerone and α-atlantone) in both zebrafish and mouse models of chemically-induced seizures
using pentylenetetrazole (PTZ). In this follow-up study, we aimed at evaluating the anticonvulsant activity of ar-
turmerone further. A more in-depth anticonvulsant evaluation of ar-turmerone was therefore carried out in the i.v. PTZ
and 6-Hz mouse models. The potential toxic effects of ar-turmerone were evaluated using the beam walking test to
assess mouse motor function and balance. In addition, determination of the concentration-time profile of ar-
turmerone was carried out for a more extended evaluation of its bioavailability in the mouse brain. Ar-turmerone
displayed anticonvulsant properties in both acute seizure models in mice and modulated the expression patterns of
two seizure-related genes (c-fos and brain-derived neurotrophic factor [bdnf]) in zebrafish. Importantly, no effects on
motor function and balance were observed in mice after treatment with ar-turmerone even after administering a dose
500-fold higher than the effective dose in the 6-Hz model. In addition, quantification of its concentration in mouse
brains revealed rapid absorption after i.p. administration, capacity to cross the BBB and long-term brain residence.
Hence, our results provide additional information on the anticonvulsant properties of ar-turmerone and support further
evaluation towards elucidating its mechanism of action, bioavailability, toxicity and potential clinical application.
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Introduction
Epilepsy is a common neurological disorder characterized by
spontaneous recurrent focal or generalized seizures that affect
the central nervous system in diverse ways. To date, epilepsy
affects about 50 million people worldwide [1] [2]. Although half
of all known epilepsy cases can be associated with different
etiologies, for the other half there is no identifiable cause. The
most frequent causes of epileptic seizures in infants are
genetic factors, perinatal hypoxia/asfixia, intracranial trauma,
congenital malformations of the brain, or infections [3] [4] [5]. In
young children and adolescents, epilepsy is usually related to
genetic factors [6], whereas in adults, the etiology can be
attributed more to cerebrovascular diseases, head injury and
brain tumors [7] [8].
The pharmacological treatment of epilepsy starts with the
administration of a single antiepileptic drug (AED) suitable for
the specific epilepsy syndrome. Selection of the appropriate
AED is based on its efficacy, tolerability and safety according to
the type of seizure. About 70% of patients become seizure-free
with single AED therapy. Nevertheless, around 30% of patients
with epilepsy remain resistant to both mono- and combinatorial
AED therapy [9] [10] [11]. Combinatorial therapy of AEDs is not
the first option as it may potentiate the occurrence of adverse
side effects due to neurotoxicity and/or hepato-toxicity [10] [12]
[13] [14] [15]. However, it is important to note that side effects
have not only been reported for AED combinatorial therapy but
also for monotherapy [10] [11] [13] [16]. Hence, the current aim
of antiepileptic drug discovery is to identify novel active
compounds that can provide a safer option with higher efficacy
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to control pharmaco-resistant seizures compared to currently
available AEDs. Such potential drug candidates may be
present in medicinal plants traditionally used against seizures
[17] [18] [19] [20], as in the case of Curcuma longa [21]. The
rhizome powder of Curcuma longa (turmeric) is commonly
used for food preparation due to its yellow color and
characteristic aroma but also in ethnopharmacology because of
its reported therapeutic properties. The long-standing role of
turmeric in traditional medicine is confirmed by its presence in
medicinal preparations described in Sushruta’s Ayurvedic
Compendium (250 B.C.) [22]. Presently, there is growing
scientific evidence that supports some of these traditional uses.
Most relevant for the field of epilepsy, the anticonvulsant
activity of turmeric has been verified in preclinical models.
These studies have focused mainly on curcuminoids
(curcumin) as active principles [23] [24] [25]. Unfortunately,
further clinical development of curcumin as a AED candidate
has been hampered due to its poor absorption by the gut and
rapid metabolism [26]. Conversely, improved bioavailability of
turmeric oil in comparison to curcuminoids has been reported
[26] [27] [28]. In addition, our previous report demonstrated that
other constituents of turmeric, namely the bisabolene
sesquiterpenoids of turmeric oil could effectively delay the
onset of chemically-induced seizures in zebrafish and mouse
models [21].
As a follow-up to our previous work, this research study
carried out additional tests on ar-turmerone to assess its
anticonvulsant activity and to investigate its probable effects on
balance and motor function. Ar-turmerone was selected from
the group of active sesquiterpenoids present in turmeric oil due
to the chemical stability conferred by its aromatic ring. The
capability of ar-turmerone to delay seizure generation was
evaluated using two acute rodent models: the i.v.
pentylenetetrazol (PTZ) timed infusion test and the 6-Hz
psychomotor model of partial epilepsy. These two models were
chosen on the basis of their proven competence for
identification of AEDs acting through a wide variety of
mechanisms of action, including novel targets (e.g.
levetiracetam) [29] [30] [31] [32] [33]. Furthermore,
neurotoxicity evaluation on potential sedative side effects was
completed using the beam walking test [34] [35] [36].
Aside from the anticonvulsant activity and neurotoxicity tests,
we investigated the concentration-time profile of ar-turmerone
in the mouse brain for a more in-depth overview of its
bioavailability. Additionally, the effects of ar-turmerone on the
expression of seizure-related genes were investigated in
zebrafish brains in an effort to identify a rational correlation with
the proven anticonvulsant activity of this compound in zebrafish
and mouse models. We also quantified changes in the
expression levels of the seizure-modulated genes c-fos and
bdnf in zebrafish larval brains [37] [38] [39] [40] [41] [42] [43].
In summary, the present study describes a series of
preclinical assays carried out to further investigate the
anticonvulsant properties and safety of ar-turmerone as a
potential drug candidate for the treatment of epilepsy.
Materials and Methods
Chemicals and reagents
Dimethyl sulfoxide (99.9%, spectroscopy grade), poly-
ethylene glycol M.W. 200 (PEG200), methanol (HPLC grade),
dichloromethane (99%, HPLC grade) and heptane (99%, HPLC
grade) were obtained from Acros Organics. Levetiracetam
(98%, HPLC grade) and pentylenetetrazol were procured from
Sigma-Aldrich. Acetonitrile (HPLC grade) was acquired from
Fisher Scientific, sodium valproate from Sanofi-Synthelabo and
diethyl ether (HPLC grade) from VWR. Propylparaben and
hexane (extra pure grade) were procured from Merck. TRIZOL
(ref.15596-026) was obtained from Invitrogen, DNase I (ref.
04716728001) from Roche and High Capacity cDNA Reverse
Transcription Kit (ref.4368814) from Applied Biosystems. Real-
time primers and probes were designed by and purchased from
IDT DNA.
Synthesis of ar-turmerone
Ar-turmerone was synthesized through air oxidation of
ketonic sesquiterpenes present in turmeric oil. Thus,
commercially available turmeric oil (2.7 g) was heated to 100°C
during 48 hours in a 10-ml round bottom flask attached to a
reflux condenser. Further isolation of ar-turmerone from
turmeric oil was achieved by column chromatography (silica,
eluent CH2Cl2-heptane 90:10).
Ethics Statement
Procedures for animal experiments described in this study
were carried out in accordance with Belgian and European
Laws, guidelines and policies for animal experimentation,
housing and care (Belgian Royal Decree of April 6th, 2010 and
European Directive 2010/63/EU on the protection of animals
used for scientific purposes of October 20th, 2010). This project
was approved by the Animal Ethics Committee of the
University of Leuven (Ethische Commissie van de KU Leuven,
approval numbers P101/2010 and P061/2013).
Mice (Mus musculus)
Male C57BI/6 mice at 8 weeks of age (20–30 g) and male
NMRI mice (± 20 g) were acquired from Charles River
Laboratories (France). The animals were maintained in a
temperature and light controlled quiet room (28 °C; 12/12-hour
light/dark cycle) in poly-acrylic cages with pellet diet and water
ad libitum. Mice were allowed to acclimate for one week (NMRI
strain) or two weeks (C57Bl/6 strain; until 10 weeks old).
NMRI mice were used for the 6-Hz psychomotor seizure
assay and quantification of ar-turmerone in brain tissue. For the
i.v. PTZ infusion evaluation and the beam walking test, C57Bl/6
mice were used.
Zebrafish (D. rerio)
AB adult zebrafish were reared under controlled conditions at
a temperature of 28.5°C and a light cycle (14/10-hours light/
dark). Eggs were collected from natural breeding and kept in
embryo medium (17 mM NaCl, 2 mM KCl, 1.8 mM Ca(NO3)2,
0.12 mM MgSO4, 1.5 mM HEPES buffer pH 7.1–7.3 and 0.6
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μM methylene blue) in an incubator under constant light and
temperature conditions. Medium refreshment and sorting of
embryos/larvae was performed in a daily basis until 7 days
post-fertilization (dpf).
Evaluation of anticonvulsant activity in the 6-Hz
psychomotor seizure mouse model
The protocol for this model was as previously described [44]
[45]. NMRI mice (30-35 g) were randomly divided into groups
of five animals. A defined period before electrical stimulation
(30 min and 24 h in our experimental set-up), vehicle
(PEG200:DMSO 1:1) or sample dissolved in vehicle were
administered intraperitoneally (i.p.) in a volume of 0.1 ml/kg
body weight. Valproic acid (300 mg/kg) and levetiracetam (50
mg/kg) were included in this evaluation as positive controls [33]
[46].
Psychomotor seizures are induced by low frequency, long
duration corneal stimulation (6 Hz, 0.2 ms rectangular pulse
width, 3 s duration) using an ECT Unit 5780 (Ugo Basile,
Comerio, Italy). Mice were manually restrained and a drop of
ocular anesthetic (0.5% xylocaine) was applied to the corneas
before electrical stimuli. The head was placed into the holder of
the ECT Unit to achieve corneal contact with the electrodes.
Then, electrical current was delivered and the mouse was
released immediately in a transparent poly-acrylic cage
(32 × 14 × 12.5 cm) for behavioral observation. Following
electrical stimulation, control group (vehicle treated) displayed
sudden behavioral arrest, whisker trembling, head nodding,
facial and mouth jerking, forelimb clonus and dorsiflexion of the
tail (Straub tail) [33] [44] [46]. Sometimes, stunning behavior
was preceded by running automatism [44]. Mice displaying
normal exploratory and locomotion behavior within a time
period shorter than 45 s after electrical stimulation were
considered protected. All experiments were carried out in a
blinded manner.
For each experiment, selection of electrical current was
based on its capability to elicit psychomotor seizures in 6 out of
6 control mice [vehicle-treated] starting from 32 - 64 mA [33]
[45]. If needed, current was increased until uniform occurrence
of convulsions was observed in all animals tested. The ECT
Unit is provided with a detector to avoid misplacing electrodes
during stimulation. All mice were euthanized at the end of the
experiment.
Evaluation of anticonvulsant activity in the timed i.v.
PTZ infusion model
C57Bl/6 mice were randomly divided into control and
treatment groups of five mice each. The methodology for this
assay was based on the one described in our previous study
[21]. Briefly, mice were restrained for tail infusion and
catheterized with 1-cm long, 29-gauge needle attached to a
polyethylene catheter. Then, vehicle/sample and PTZ were
infused intravenously; vehicle/sample first and after 10 min,
PTZ was also administered via catheter (7.5 mg/ml; 150 µL/
min). During PTZ infusion, mice were observed for the onset of
behavioral events such as ear, tail and myoclonic twitch,
forelimb clonus, falling, tonic hindlimb extension and death.
PTZ doses needed to trigger these parameters were calculated
in reference to time latencies between the start of PTZ infusion
and the appearance of the aforementioned convulsive
episodes. At death, PTZ infusion was terminated. In case of
non-occurrence of death, infusion was stopped at 5 min and
surviving mice were euthanized immediately. Control groups
were always included in every test due to a variation observed
from batch to batch regarding PTZ doses to generate
behavioral events in mice. Levetiracetam (50 mg/kg) was also
included as positive control [30] [47].
Beam walking test
C57BI/6 mice (10 weeks old) were divided in groups of five.
Blinded evaluation was performed to lessen observer bias. All
mice were trained until proficiency to walk along a wooden
beam without pausing was achieved. The ‘beam walking test’
apparatus consists of a flat bench (70 x 35 cm) with a wooden
beam (70 cm long, 1 cm diameter) located 31.5 cm above the
bench and held to it on two posts. Two points on the beam
were labeled as ‘start’ and ‘end’ areas to allow timing of the
animal when walking across the beam. ‘Start –point’ was the
site where the mouse was located to begin the test; the ‘end-
point’, the place in front of a dark goal box (20 x 10 x 10.5 cm)
with food pellets inside. Following training, every mouse was
i.v. administered vehicle (PEG200:DMSO 1:1), sample (ar-
turmerone 50 mg/kg) or positive control (diazepam 1 mg/kg)
according to the treatment group. Ten minutes after
administration, the mouse was placed on the tip of the beam at
the ‘start-point’ facing towards the beam. The number of
footslips, falls and total time on beam (from ‘start’ to ‘end’
points) were noted [35] [36] [48]. If a mouse fell, the animal was
returned to the site where it fell from, until completion of beam
crossing [48].
Determination of ar-turmerone in mouse brain extract
Ar-turmerone administration.  Three NMRI mice per
dosage group were analyzed at each time-point. A dose of 50
mg/kg of ar-turmerone in PEG200:DMSO 1:1 was administered
intraperitoneally (i.p.). Dose and route of administration were
selected on the basis of the effectiveness of ar-turmerone to
control seizure generation in the 6-Hz psychomotor seizure
test.
Collection of samples.  Transcardial perfusion was applied
to mice after defined time-points of drug administration (15 min,
30 min, 1 h, 6h, 24 h) in order to obtain bloodless brain
samples. Brains were separated by dissection, washed with
saline solution to remove excess surface blood and dried on
filter paper. Brains were individually weighed and mixed with
hexane (1.5-fold of weight) using a homogenizer (Polytron®
PT1200E, Kinematica). Hexane brain extract (supernatant) was
collected after centrifugation at 2000 rpm (10 min). Hexane
was selected due to its efficiency in the extraction of lipophilic
analytes from brain tissue [49] [50].
Preparation of samples for HPLC analysis.  An aliquot of
100 µL of brain extract was dried by passing a slow stream of
nitrogen over the sample at room temperature to eliminate the
solvent. Residue was dissolved in 100 µL methanol. Solution
was vortexed (1 min) and centrifuged at 10.000 rpm (10 min).
For HPLC analysis, an aliquot of 20 µL of the clear supernatant
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was injected. Internal standard (IS) propylparaben was added
to obtain a final concentration of 0.25 µg/mL.
RP-HPLC method for determination of ar-
turmerone.  Brain samples were analyzed on LaChrom Elite
HPLC System [VWR Hitachi] equipped with diode array
detection (DAD). Chromatographic separation was performed
on a Phenomenex reversed phase column type Luna 3u C18
[150 × 4,6 mm 3 µm] attached to an Phenomenex guard
column C18 (4 × 3 mm). The column was operated at a flow
rate of 1 ml/min at room temperature (detection wavelength:
240 nm). Samples were analyzed using gradient elution
consisting of HPLC grade acetonitrile and Milli-Q purified water
according to Mehrotra et al. [51].
Calibration curve.  A calibration curve was used to estimate
the linearity and reproducibility of the HPLC method. Seven
standard solutions with concentrations ranging from 0.5 to 6
µg/mL (n=3) were prepared using methanol. IS was added to
the standard solutions to yield a final concentration of 0.25
µg/mL. Samples were analyzed according to described
procedures.
Recovery of ar-turmerone.  Mouse brain homogenate
samples (n=3) were spiked with ar-turmerone to obtain final
concentrations of 2 and 4 µg/mL. Likewise, IS was added to all
samples (final concentration: 0.25 µg/mL). Extraction and
analysis of samples was performed according to
aforementioned procedures.
Accuracy and precision (RSD).  Intra- and inter-day
accuracy was determined at concentrations of 2 and 4 µg/mL in
samples (n=3) that were analyzed three times per day within a
3-day period.
Gene expression of brain neuromarkers in zebrafish
larvae
Seven-dpf larvae of the AB strain (10 per group) were
exposed to 46 µM ar-turmerone (AT) or vehicle (1% DMSO in
embryo medium) for 1 h with subsequent exposure to 20-mM
PTZ. Total RNA from the group of fish was extracted with 1 ml
TRIZOL protocol, DNase-treated (DNase I) and subsequently
reverse transcribed using random hexamers priming and High
Capacity cDNA Reverse Transcription Kit. Synthesized cDNA
was quantified using the PrimeTime qPCR assay (Integrated
DNA Technologies). Primer and probe sequences are indicated
in Table 1. Tubulin was used as a reference gene as the
stability of its expression was previously assessed for these
treatments against beta-actin (data not shown), whereas the
expression levels of tubulin were closer to the genes of
interest.
Statistical Analysis
All statistical analyses were performed using GraphPad™
Prism v.5 (GraphPad Software, Inc.). Anticonvulsant activity of
rodents in the 6-Hz psychomotor seizure mice model was
evaluated using Fisher’s exact test. Unpaired Student’s t-test
was used to determine significant differences among control
and treatment groups in the timed i.v. PTZ model. Previous
assessment of normality was completed using the D’Agostino
& Pearson test. For the beam walking test and gene
expression analysis of brain neuromarkers, p-values (p<0.05)
were calculated using one-way ANOVA followed by Dunnett’s
multiple comparison tests. In both cases, the ANOVA factor
was ‘treatment group’. ‘Treatment group’ refers to treatment
with vehicle (PEG200:DMSO), ar-turmerone, or diazepam for
the beam walking test and, to vehicle (PEG200:DMSO) and
pentylenetetrazol for the gene expression analysis
experiments.
Results
Synthesis of ar-turmerone
After air oxidation, a yield of 1.4 g (52%) of ar-turmerone was
obtained from turmeric oil as a pale yellow liquid; 1H NMR (300
MHz, CDCl3) δ 7.10 (s, 4H), 6.02 (s, 1H), 3.29 (m, 1H), 2.64
(m, 2H), 2.31 (s, 3H), 2.11 (s, 3H), 1.5 (s, 3H), 1.42 (d, 2J = 7.0
Hz, 3H). No traces of α-, β-turmerone were observed in the 1H
NMR spectra of the treated oil. The enantiomeric purity of the
(R)-ar-turmerone was confirmed by comparison of its optical
rotation with the value reported in the literature [52] [53].
Evaluation of anticonvulsant activity in the 6-Hz
psychomotor seizure mouse model
Following electrical stimulation (performed 30 min after ar-
turmerone administration), all treated mice (n=6) were
protected at doses ranging between 0.1 and 50 mg/kg (p<0.05)
(Figure 1A). Even after 24 h i.p. administration of ar-turmerone
(50 mg/kg), 70% of treated mice were protected following
seizure induction (n=10; p<0.05) (Figure 1B). For positive
controls, complete protection (n=6; p<0.05) was detected with
levetiracetam (50 mg/kg) and sodium valproate (300 mg/kg)
(Figure 1A). Electrical current in all cases was 44 mA.
Table 1. Primer and probe sequences for gene expression analysis of neuromarkers in the zebrafish brain.
Gene forward 5' to 3' reverse 5' to 3' probe 5' to 3'
c-fos GTATTACCCGCTCAACCAGAC TCCAGTAACCCTCATTTTGGG CGCAGCTCAATCCTACAACCCGA
bdnf AGCTGAAGAGACAACTTGCAG CCATAGTAACGAACAGGATGGTC TGCGCGGAGGTCTTATCCAAAACA
gabra1 ACTCTGCTTTACACCATGAGG CTCGAGTCCAAACGTACACC AAATTTGAGAGGGCAAGCATGGGC
il10 AGCTCCGTTCTGCATACAAAG GGTCTCCAAGTAGAAATGCAGG CAGTCCCTATGGATGTCACGTCATGAAC
tub ACTACACTATTGGCAAGGAGC GAAACCCTGGAGACCTGTG TGGTCAGACAGTTTGCGAACCCT
c-fos: proto-oncogene c-fos, gabra1: gamma-aminobutyric acid receptor-A, bdnf: brain-derived neurotrophic factor, il10: interleukin-10
doi: 10.1371/journal.pone.0081634.t001
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Evaluation of anticonvulsant activity in the timed i.v.
PTZ -infusion model
PTZ (7.5 mg/ml) infused intravenously at a constant rate
(150 µL/min) in control group mice (VHC) elicited characteristic
behavioral events: ear, tail and myoclonic twitch, forelimb
clonus, falling, tonic hindlimb extension and death. Ar-
turmerone at the dose of 1 mg/kg protected mice by raising the
threshold of PTZ needed to trigger tonic hindlimb extension
and death (p<0.05). Furthermore, ar-turmerone at 20 mg/kg
increased the PTZ dose necessary to cause death in mice
(p<0.05) (Figure 2; Table 2). A similar increase in the PTZ dose
required to ellicit death in treated mice (p < 0.05) was observed
for levetiracetam at 50 mg/kg (positive control) (Figure 2; Table
2).
Beam walking test
The dose of ar-turmerone and the administration route used
in this assay were based on the same conditions that showed
anticonvulsant activity in the i.v. PTZ model. No effect on
balance was observed in C57Bl/6 mice after i.v. administration
of ar-turmerone (50 mg/kg) in this motor function test. Behavior
and performance of mice treated with ar-turmerone were
comparable to the control group (VHC) (Figure 3). Diazepam
(DZP) significantly increased the number of foot slips (p<0.05)
and the occurrence of falling (p<0.05) as well as the total time
needed for mice to cross the beam (p<0.05) (Figure 3).
Likewise for NMRI mice, no differences in motor function/
balance were observed between vehicle-treated (control group)
and ar-turmerone-treated animals after an intra-peritoneal dose
of 50 mg/kg (data not shown).
Determination of ar-turmerone in mouse brain
homogenate
Selectivity.  The method for the chromatographic analysis of
brain homogenate samples showed no interference from
endogenous components at the retention times of IS (2.6 min)
and ar-turmerone (6.9 min) in the chromatograms. Therefore, it
Figure 2.  Evaluation of the anticonvulsant activity of ar-
turmerone (AT) in the timed i.v.  PTZ infusion model.
Radar graphic depicts the doses of PTZ required to trigger
seven characteristic behavioral events (ET: ear twitch, MT:
myoclonic twitch, TT: tail twitch, FC: forelimb clonus, F: falling,
THE: tonic hindlimb extension, D: death) after i.v.
administration of AT at 1 and 20 mg/kg compared to vehicle-
treated mice (control). Levetiracetam (LEV) 50 mg/kg was
included as a positive control. Results are expressed as
relative values compared to control (set as 100%). For reasons
of clarity, mean values (± SD) and statistically significant
differences are not shown here (for details see Table 2).
doi: 10.1371/journal.pone.0081634.g002
Figure 1.  Evaluation of the anticonvulsant activity of ar-turmerone (AT) as determined by the 6-Hz model.  A) After 30 min of
i.p. administration, complete protection was observed for ar-turmerone at a dose range of 0.1 - 50 mg/kg. A group of vehicle-treated
mice (VHC) was included as a negative control. Sodium valproate at 300 mg/kg (VAL300) and levetiracetam at 50 mg/kg (LEV50)
were used as positive controls. B) After 24 h i.p. administration (50 mg/kg), protection was observed after electrical induction.
Statistically significant differences between control (VHC) and sample groups are labeled as * for p < 0.05 (Fisher’s exact test).
doi: 10.1371/journal.pone.0081634.g001
Ar-turmerone: Anticonvulsant and Safety Evaluation
PLOS ONE | www.plosone.org 5 December 2013 | Volume 8 | Issue 12 | e81634
was found to be specific and efficient for our purposes (Figure
4).
Linearity.  The calibration curve of ar-turmerone from
standard solutions was linear over the concentration range of
0.5 - 6 µg/mL (n=3; r=0.994).
Recovery.  The mean (± SD) recovery of ar-turmerone from
brain homogenate at 2 and 4 µg/mL was 84.2 ± 4.0% and 85.5
± 10.4%, respectively.
Accuracy and precision.  Accuracy and precision of the
HPLC methodology for ar-turmerone determination in brain
homogenate are listed in Table 3.
Determination of ar-turmerone.  The characterized HPLC
method was used for determination of the concentration-time
profile of ar-turmerone in mouse brain extract. Following i.p.
dosage of 50 mg/kg of ar-turmerone, chromatographic analysis
of samples showed evidence for the presence of this
compound in mouse brain at 15 min and up to 24 hours after
administration (Figure 5).
Gene expression of brain neuromarkers in zebrafish
larvae
Concentration of ar-turmerone used in this test was
determined by previous results of positive anticonvulsant
activity at 46 µM in the zebrafish model [21]. No signs of
toxicity such as lack of startle response to plate taps, changes
in heart rate or circulation, presence of edema, loss of posture,
paralysis and/or death were observed in zebrafish larvae at this
concentration. Ar-turmerone significantly downregulated c-fos
epression induced by PTZ (p<0.001). In the absence of PTZ,
Table 2. Timed i.v. PTZ infusion model: PTZ doses.
 PTZ dose required [mg/kg]
 Control AT Control AT Control LEV
 [VHC] 1 mg/kg [VHC] 20 mg/kg [VHC] 50 mg/kg
ET 73,2 ±17,4
59,5 ±
19,7
40,2 ±
11,2
49,3 ±
10,7
51,7 ±
11,9
49,0 ±
12,0
MT 82,6 ±20,9
71,4 ±
20,5
44,6 ±
10,3
58,7 ±
15,1
56,3 ±
13,5
56,6 ±
12,8
TT 78,7 ±22,6
61,0 ±
20,5
43,9 ±
12,7
55,1 ±
14,2
53,7 ±
12,1
52,7 ±
13,8
FC 93,1 ±27,2
77,9 ±
24,2
66,4 ±
14,8
69,4 ±
16,0
70,6 ±
16,0
79,5 ±
26,1
F 89,5 ±14,1
85,2 ±
19,1
59,5 ±
21,4
76,6 ±
14,5
66,3 ±
12,7
77,5 ±
25,9
THE 111,9 ±17,5
162,3 ±
43,3 *
110,0 ±
20,1
117,4 ±
26,3
100,6 ±
16,7
119,5 ±
23,2
D 134,0 ±20,7
196,6 ±
42,2 *
132,8 ±
18,8
189,8 ±
55,3 *
120,1 ±
18,9
185,2 ±
44,8 *
ET: ear twitch, MT: myoclonic twitch, TT: tail twitch, FC: forelimb clonus, F: falling,
THE: tonic hindlimb extension, D: death
VHC: vehicle, AT: ar-turmerone, LEV: levetiracetam
Values are expressed as mean values (± SD). Statistically significant differences
between sample and control group are labeled as * for p < 0.05 (unpaired
Student's t-test).
doi: 10.1371/journal.pone.0081634.t002
bdnf expression was upregulated in the ar-turmerone treated
group (p<0.01). After PTZ treatment, bdnf was highly
expressed in both groups (vehicle-treated and ar-turmerone-
treated larvae); increase of bdnf expression was found to be
significant for the vehicle-treated group when compared to the
control group (p<0.05). Expression patterns of the GABA-A
receptor and IL10 were not affected by ar-turmerone treatment
(Figure 6).
Discussion
In line with NIH guidelines [54], we conducted our research
with the goal of using key acute seizure models that could
potentially increase our chances of identifying compound/s
acting through novel mechanisms of action or that might
constitute a safer alternative than the available
pharmacological options. In this study, we also propose a
simple and efficient method for synthesis and isolation of ar-
turmerone from turmeric oil, as further in vivo characterization
of the pharmacological properties of ar-turmerone will require
considerably larger amounts of compound. Turmeric oil is
composed mainly of bisabolene sesquiterpenoids such as ar-
turmerone, α-turmerone, β-turmerone and α-atlantone [55]. It
has been reported that ketonic sesquiterpenes of turmeric oil
such as α-turmerone and β-turmerone can be converted to ar-
turmerone by air oxidation over time [52] [53] [56]. Thus,
different oxidation conditions were investigated to increase the
content of ar-turmerone in turmeric oil. It was observed that
oxidation of turmeric oil with p-chloranil at different
temperatures did not lead to a complete conversion of α- and
β-turmerone to ar-turmerone. Alternatively, treatment with 2,3-
dichloro-5,6-dicyano-1,4-benzoquinone (DDQ) at 120°C for 24
h resulted in a satisfactory increase in ar-turmerone yield from
30% to 48% after column chromatography purification.
However, remaining chlorinated products (trace amounts) were
also detected with this method. A satisfactory result was finally
achieved by using air as the oxidizing agent at 100°C over a
period of 48 h. Interestingly, no trace of α and β-turmerone was
observed in the crude NMR spectra of the treated oil. Hence,
this method was found appropriate due to a significant
conversion (52%) of different ketonic sesquiterpenes from
turmeric oil to ar-turmerone with a high purity level as well.
For anticonvulsant activity evaluation, the i.v. PTZ timed
infusion test and the 6-Hz psychomotor model of partial
epilepsy were selected due to their unique sensitivity for
identification of AEDs with a wide range of mechanisms of
action [29] [30] [31] [32] [33] [44] [57] including detection of the
anticonvulsant properties of levetiracetam that were
“overlooked” by MES and s.c. PTZ tests [30] [33] [58].
Levetiracetam is an AED acting predominantly on a different
target to those already known – i.e. via specific binding to the
synaptic vesicle protein SV2A [59] [60]. Our previous results
from the i.v. PTZ test revealed a clear anticonvulsant activity of
ar-turmerone at a dose of 50 mg/kg [21]. To complete the
dose-response analysis for this test, two additional doses of ar-
turmerone were evaluated (1 and 20 mg/kg). In both cases, a
considerable increase in PTZ dose required to cause death in
mice was observed. Positive activity of levetiracetam in this
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Figure 3.  Evaluation of the effect of ar-turmerone on mouse motor function and balance.  An intravenous dose of 50 mg/kg of
ar-turmerone (AT) does not cause any alteration of motor skills in mice. Sensitivity of this model was confirmed by detection of
motor and balance deficits induced by diazepam (DPZ) in mice at 1 mg/kg. Compared to control group (VHC), DZP-treated mice
displayed a significant increase in number of footslips (A), falls (B) and time to reach goal box (C). Statistically significant differences
between control and sample groups are labeled as ** for p < 0.001 (one-way ANOVA test).
doi: 10.1371/journal.pone.0081634.g003
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Figure 4.  Representative HPLC chromatograms of mouse brain homogenate analysis for ar-turmerone determination.  A)
blank mouse brain extract, B) blank mouse brain extract spiked with ar-turmerone (AT) and internal standard (IS) and C) brain
extract sample of a dosed mouse.
doi: 10.1371/journal.pone.0081634.g004
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model confirms previous results from Mandhane et al. [30] and
corroborate its sensitivity for identifying potential drug
candidates likely acting through novel mechanisms of action.
In addition, the clear protective activity of ar-turmerone in the
6-Hz model revealed its potency in controlling seizure
generation within an extensive range of effective doses (0.1 -
50 mg/kg) at 30 min and up to 24 h after i.p. administration.
Along with its demonstrated potency, these results provide
evidence for a wide therapeutic window that potentially lowers
Table 3. Intra-, inter-assay accuracy and precision of the
method for determination of ar-turmerone in brain extracts.
Concentration [ug/mL] Accuracy % RSD %
 Intra-assay Inter-assay Intra-assay Inter-assay
2 99,7 99,5 1,4 0,1
4 99,1 100,5 2,9 1,2
doi: 10.1371/journal.pone.0081634.t003
the chance of side effects. A correlation between the protective
activity of levetiracetam in the 6-Hz model [33] [46] [57] [58]
[60] [61] and its proven effectiveness as a monotherapy and
‘add-on’ drug for the treatment of refractory human epilepsies
[62] [63] [64] [65] [66] supports the usefulness of this acute
model for the identification of AED candidates acting through
novel mechanisms of action.
Evaluation of potential toxicity is also crucial in the search for
novel AEDs. For this purpose, we used the beam walking test
which possesses higher sensitivity when compared to the
rotarod test for measuring motor function and balance in mice
[48]. Results from the beam walking test lead to a more
accurate prediction of benzodiazepine-induced motor
coordination deficits at relatively low GABA-A receptor
occupancy (e.g 30% for diazepam) in contrast with rotarod
performance which is affected only at much higher levels (72%)
of receptor occupancy [48] [67]. It has been stated that
evaluation of known AEDs in the beam walking test is more
closely related to what is reported in clinical trials [67]. After i.v.
and i.p. administration of 50 mg/kg of ar-turmerone [highest
Figure 5.  Concentration – time profile of ar-turmerone in mouse brain extracts.  Chromatographic analysis of these samples
showed evidence of the presence of ar-turmerone at 15 min and up to 24 hours after i.p administration of 50 mg/kg.
doi: 10.1371/journal.pone.0081634.g005
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tested active dose], mice did not display any alteration in beam
walking performance. No significant differences in the number
of footslips, falls and time on beam were observed when
compared to the vehicle injected-group. Consistently, identical
results were found in NMRI mice after i.p. administration of 50
mg/kg [data not shown]. These results suggest ar-turmerone as
a potential drug candidate with no effect on locomotor activity
or balance in rodents and a high probability of comparable
safety in humans as well. Our results are consistent with the
findings of Liju et al. regarding non-toxicity of turmeric oil,
containing 61.7% ar-turmerone, after acute and subchronic oral
administration in rats [68]. The safety of the main constituent of
turmeric oil, ar-turmerone, has also been verified by studies in
humans after oral administration of turmeric oil over three
months [69]. With respect to safety, one of the most common
side effects of the available AEDs is cognitive impairment.
Turmeric exhibits an additional advantage in this regard. Better
cognitive performance in elderly people has been associated
with turmeric consumption [70]. Of course, whether ar-
turmerone is the main constituent of turmeric responsible for
this observed increase in cognitive performance remains to be
determined. Nevertheless, the potential add-on benefit if this
were to be the case is intriguing to say the least. Furthermore,
the use of turmeric for centuries as a spice, especially in Indian
food, confers additional support for its safety for human
consumption. In fact, it has been reported that a diet including
daily consumption of turmeric of up to 1.5 g or even 4 g per
person (around 10 - 30 mg of ar-turmerone) is not associated
with adverse effects in humans [71] [72] [73].
Noteworthy is the relationship between the positive activity of
ar-turmerone in the i.v. PTZ seizure test and the safety
displayed in the beam walking test. The i.v. PTZ test is able to
identify a wide variety of AEDs acting through different
mechanisms of action including GABA-related AEDs [30].
Seizure generation is then controlled through enhancement of
GABAergic transmission in the case of GABA-related AEDs
[31] [74]. However, these AEDs are known to induce muscle
hypotonia and sedation as side effects [e.g. diazepam] [75]
[76]. Thus, the use of the beam walking test is not only
constrained to evident impairment of locomotor function/
Figure 6.  Evaluation of the effect of ar-turmerone on seizure-related marker expression in zebrafish brains.  Ar-turmerone
(AT) downregulated PTZ-induced c-fos expression and upregulated bdnf expression in the abscense of PTZ treatment. Statistically
significant differences between groups: control (VHC), vehicle treated exposed to PTZ (PTZ), ar-turmerone treated (AT) and ar-
turmerone treated exposed to PTZ (AT+PTZ) are labeled as * for p < 0.05 and ** for p < 0.001 (one-way ANOVA test).
doi: 10.1371/journal.pone.0081634.g006
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balance after AED administration but also provides important
hints about the potential mechanisms of action of ar-turmerone.
Normal performance of mice in this test after administration of
ar-turmerone suggests that the anticonvulsant activity of ar-
turmerone may not be mainly exerted by GABA-mediated
inhibition. Confirmation of the anticonvulsant properties of ar-
turmerone without sedation constitutes an important advantage
over the known AEDs (at least in the preclinical stage). Indeed,
more specific studies about the possible mechanism/s of action
of ar-turmerone are still needed.
Determination of the concentration - time profile of ar-
turmerone in mouse brains after i.p. administration (50 mg/kg),
evidenced rapid absorption from the peritoneum to the brain.
Detection of ar-turmerone in brain tissue was possible after 15
min and up to 24 hours after administration. This finding is
consistent with the results from the 6-Hz model where
protection against electrical stimulation is observed in 70% of
treated mice up to 24 h after i.p. administration of ar-turmerone.
Our results underscore the ability for ar-turmerone to penetrate
the BBB and, in line with Prakash et al. [27], supports its high
absorption and bioavailability. High potency of ar-turmerone
may be supported by the fact that detected concentrations in
the brain are quite low if compared to available AEDs. After
administration of effective doses of different well-known AEDs,
levels in brain tissue were found to be between the range of
2.59 - 26.61 µg/g [77]. On the other hand, detection of low
concentrations of ar-turmerone in brain tissue may also be
explained by the generation of ar-turmerone metabolites and
thus, the true active compound may have been overlooked
using this protocol. Certainly, there are additional studies that
need to be completed to understand the bioavailability of ar-
turmerone better. A further characterization of the
pharmacokinetic profile of ar-turmerone is currently in our
interest since it will provide additional information about the
relationship between the concentration-time profile of the active
compound/metabolite in brain and its therapeutic effects,
dosage, route and frequency of administration, etc.
Interestingly, after achieving peak concentration in brain (212
ng/mg) at 30 min, the levels of ar-turmerone were maintained
in the range of 200 ng/ml for up to 24 hours. This finding may
be explained by the hypothesis of a ‘depot’ formation of ar-
turmerone at level of the peritoneum after administration
through this route. Thus, a continued gradual release of ar-
turmerone along with its capability to cross BBB could explain
its sustained presence in the brain over a long period.
In addition to the rodent studies, modulation of the seizure-
related markers (c-fos, gamma-aminobutyric acid receptor-A
[gabra], brain-derived neurotrophic factor [bdnf] and
interleukin-10 [il10]), was analyzed in zebrafish brains after
treatment with ar-turmerone in the presence and absence of
PTZ. Genes for this evaluation were selected on the basis of
their key role in seizure-related pathogenesis. The proto-
oncogene c-fos is upregulated significantly in the brain in
response to triggering stimuli (e.g. seizures) in both zebrafish
and rodent models [37] [38] [39] [40]. The gene gabra is a
crucial link in the main inhibitory neurotransmitter pathway of
the CNS, with changes in its expression or mutations are
closely associated with epileptogenesis [78]. BDNF
upregulation has been associated with antidepressant effects
[79] [41] while its deficits have been linked with a number of
neurodevelopmental, neurodegenerative, and neuropsychiatric
disorders [42]. BDNF also plays a role in the pathogenesis of
temporal lobe epilepsy (TLE) by enhancing neuronal outgrowth
and mossy fiber sprouting [43]. IL10 prevents neuronal damage
caused by excess of excitatory neurotransmitters and reduces
the harmful effects of hypoxia as well [80]. Our results show a
significant decrease in c-fos transcription in larvae treated with
ar-turmerone and exposed to PTZ. Thus, considering that c-fos
is a marker of seizure severity, this result suggests that ar-
turmerone plays a crucial role in controlling abnormal neuronal
activity accompanying PTZ-induced seizures [37]. In addition,
comparison of the results from zebrafish exposed to vehicle
only and ar-turmerone only, revealed bdnf upregulation in the
brain after ar-turmerone treatment. Hence, bdnf upregulation
may underlie potential antidepressant activity of ar-turmerone
and/or neuroprotective effects. On the other hand, an increase
of bdnf transcription was observed for both groups [vehicle-
treated and ar-turmerone treated] after PTZ exposure. This
observation is in line with the reported upregulation of BDNF
[protein and mRNA] at the hippocampal level in seizure animal
models [81][82][83]. Under oxidative stress conditions [e.g.
caused by PTZ exposure], an initial marked downregulation of
BDNF, triggers a subsequent activation of pro-BDNF pathways
[84].. Thus, the increased expression of bdnf in the PTZ-only
treated group appears to be due to the proconvulsant
properties of PTZ. However, the upregulation of bdnf
expression in the case of ar-turmerone-treated larvae does not
appear to be due to an intrinsic proconvulsant activity of the
compound as c-fos expression is significantly downregulated
after combined treatment with ar-turmerone and PTZ. Thus, it
could be inferred that the increase in bdnf expression in ar-
turmerone + PTZ treated larvae was not only ’triggered’ by PTZ
but also related to an intrinsic effect of ar-turmerone. Although
additional confirmatory studies are clearly warranted, these
findings suggest that ar-turmerone may modulate anti-
depressant activity mediated by enhancement of BNDF mRNA
expression in the brain.
In summary, our results suggest ar-turmerone as a
potentially safe AED candidate with influence on the
expression of two relevant seizure-related genes and proven
activity in two acute seizure mouse tests (including a proposed
pharmaco-resistance model). Future experiments using other
models (e.g. kindling, status epilepticus, post-stroke, post-
traumatic brain, status epilepticus, genetic models, among
others) are still necessary to characterize the potential clinical
application of ar-turmerone further. Hence, the present study
supports continued research for investigating the
anticonvulsant properties of ar-turmerone, likely as an
alternative for pharmaco-resistant cases and/or clinical cases
of adverse effects with currently available AEDs.
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